165 related articles for article (PubMed ID: 38704377)
1. Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment.
Yu P; Hu C; Ding G; Shi X; Xu J; Cao Y; Chen X; Wu W; Xu Q; Fang J; Huang X; Yuan S; Chen H; Wang Z; Huang L; Pang F; Du Y; Cheng X
Nat Commun; 2024 May; 15(1):3771. PubMed ID: 38704377
[TBL] [Abstract][Full Text] [Related]
2. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.
Xu X; Li Y; Zhang R; Chen X; Shen J; Yuan M; Chen Y; Chen M; Liu S; Wu J; Sun Q
J Ethnopharmacol; 2023 Jul; 311():116450. PubMed ID: 37023839
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
4. The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin.
He W; Zhang D; Jiang J; Liu P; Wu C
Med Oncol; 2014 May; 31(5):950. PubMed ID: 24722794
[TBL] [Abstract][Full Text] [Related]
5. [A Case of Taxane-Pretreated Metastatic Gastric Cancer with Excellent Response to Nab-Paclitaxel].
Kawabata R; Kimura Y; Kawase T; Yoshikawa M; Kameda C; Matsumura T; Koga C; Murakami M; Hirota M; Noura S; Ikenaga M; Shimizu J; Hasegawa J
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2088-90. PubMed ID: 26805273
[TBL] [Abstract][Full Text] [Related]
6. Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.
Nadauld LD; Garcia S; Natsoulis G; Bell JM; Miotke L; Hopmans ES; Xu H; Pai RK; Palm C; Regan JF; Chen H; Flaherty P; Ootani A; Zhang NR; Ford JM; Kuo CJ; Ji HP
Genome Biol; 2014 Aug; 15(8):428. PubMed ID: 25315765
[TBL] [Abstract][Full Text] [Related]
7. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Long-Term Survival after Surgeries for Gastric Cancer and Metachronous Ovarian Metastasis].
Yoshida T; Wajima N; Akasaka H; Sakuraba S; Muroya T; Kubo N; Okano K; Uchida C; Hakamada K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2006-8. PubMed ID: 26805246
[TBL] [Abstract][Full Text] [Related]
10. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Komatsu M; Hiyama K; Tanimoto K; Yunokawa M; Otani K; Ohtaki M; Hiyama E; Kigawa J; Ohwada M; Suzuki M; Nagai N; Kudo Y; Nishiyama M
Mol Cancer Ther; 2006 Mar; 5(3):767-75. PubMed ID: 16546992
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
Wiseman LR; Spencer CM
Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
[TBL] [Abstract][Full Text] [Related]
12. Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type.
Tuan TF; Tsai ML; Yeh KC; Huang HC; Chung CT; Huang CL; Han CH; Chen CP; Wang MH; Shen CC; Lai YK; Lee WS; Hwang LL; Chen CT
Cancer Chemother Pharmacol; 2010 Sep; 66(4):773-83. PubMed ID: 20044750
[TBL] [Abstract][Full Text] [Related]
13. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.
Chien J; Aletti G; Baldi A; Catalano V; Muretto P; Keeney GL; Kalli KR; Staub J; Ehrmann M; Cliby WA; Lee YK; Bible KC; Hartmann LC; Kaufmann SH; Shridhar V
J Clin Invest; 2006 Jul; 116(7):1994-2004. PubMed ID: 16767218
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.
Kim ST; Sa JK; Oh SY; Kim K; Hong JY; Kang WK; Kim KM; Lee J
Genome Med; 2021 Jan; 13(1):11. PubMed ID: 33494793
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Satoh T; Xu RH; Chung HC; Sun GP; Doi T; Xu JM; Tsuji A; Omuro Y; Li J; Wang JW; Miwa H; Qin SK; Chung IJ; Yeh KH; Feng JF; Mukaiyama A; Kobayashi M; Ohtsu A; Bang YJ
J Clin Oncol; 2014 Jul; 32(19):2039-49. PubMed ID: 24868024
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
[TBL] [Abstract][Full Text] [Related]
19. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
[TBL] [Abstract][Full Text] [Related]
20. Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients.
Gao J; Huo S; Zhang Y; Zhao Z; Pan H; Liu X
Cancer Med; 2023 Jan; 12(1):913-929. PubMed ID: 35621244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
